Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate

J. Douxfils, J.-M. Dogné, F. Mullier, B. Chatelain, Y. Rönquist-Nii, R.E. Malmström, P. Hjemdahl

Résultats de recherche: Contribution à un journal/une revueArticleRevue par des pairs

187 Téléchargements (Pure)

Résumé

Ways to monitor dabigatran etexilate (DE) therapy would be useful in certain situations. Functional assays such as aPTT or Hemoclot® Thrombin Inhibitor (HTI) have been proposed to evaluate dabigatran concentrations, but previous findings are based on in vitro studies and results must be confirmed in clinical samples. The aim of this study was to compare aPTT and HTI measurements with liquid chromatography- tandem mass spectrometry (LC-MS/MS) measurements of dabigatran in plasma samples from DE treated patients. Seventy-one plasma samples were included. aPTT was performed using STA-CKPrest® and SynthASil®. HTI was performed according to instructions from the manufacturer. The LC-MS/MS method utilised dabigatran- d3 as internal standard. The plasma concentration range was 0 to 645 ng/ml as measured by LC-MS/MS. Overall, the HTI and LC-MS/ MS analyses correlated well (r2=0.97). The Bland-Altman analysis showed a mean difference of 9 ng/ml (SD: 20 ng/ml). However, the HTI performed poorly at concentrations 50 ng/ml. Quantification of lower dabigatran levels in DE-treated patients requires the "reference" LC-MS/MS method.
langue originaleAnglais
Pages (de - à)543-549
Nombre de pages7
journalThrombosis and Haemostasis
Volume110
Numéro de publication3
Les DOIs
Etat de la publicationPublié - sept. 2013

Empreinte digitale Examiner les sujets de recherche de « Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate ». Ensemble, ils forment une empreinte digitale unique.

Contient cette citation